Open in interactive viewer → charts, metric popovers & call review

Surgical Science Hits the Margin, Misses the Growth — and Finally Has a Buyback Date

Flat Q3 sales hide a genuine U.S. turnaround, a fading Intuitive overhang, and a new ultrasound product that management thinks opens a much larger TAM
SUS.ST · Earnings Call · 2026-11-12

A quarter that is two stories at once

Surgical Science reported sales of SEK 260 million, down 1% year over year — a number that would normally sink a small-cap MedTech name. But the P&L underneath told a different story: gross margin up three percentage points to 68%, adjusted EBIT of SEK 38 million, a 15% margin, exactly at the company's own financial target. CFO Anna Ahlberg framed it plainly: “Sales came in at SEK 260 million. That was down 1%, both in SEK and also in FX adjusted. But it is, again, worth remembering that Q3 last year was -- that was a really strong quarter.” — Anna Ahlberg, CFO · 2026-11-12 That is the tension of this report. Profitability has arrived a year early; growth has not arrived at all. CEO Tom Englund said it directly: “Growth is though not yet at our target level, and we have been open about that for 2026. 2027 is the year we expect to reach our financial targets.” — Tom Englund, CEO · 2026-11-12 For a company that only twelve months ago was absorbing an acquisition and a customer-contract shock, hitting the margin while missing the top line is progress — just not the kind that re-rates a stock on its own.

The U.S. finally turned — and it is broad, not a one-off

The real signal is geographic. U.S. sales grew almost 50% year over year; the Americas region as a whole grew 30%. That is a sharp reversal from the first half, when management was openly describing a hesitant U.S. customer base with long purchasing decisions. The fix was operational, not cyclical: a restructured sales force, higher prices, and more direct sales replacing distributor revenue. Englund was careful to pre-empt the "one big deal" read: “It's not like one single deal, but rather broad-based, and it has been building quarter-over-quarter.” — Tom Englund, CEO · 2026-11-12 That shift is visible in the company's own keyword record. U.S. sales sits near the top of this quarter's themes, and Educational Products is carrying the narrative — the business area that was the problem child is now the one management leads with. Analysts noticed: Christian Lee of Pareto pressed on whether the highest-ever Q3 for Edu could be extrapolated, and Englund answered with a market-growth estimate of "close to 15% to 20%" inherent to the segment, plus price and direct-sales levers still working through. The margin improvement is the compound effect of all of it: more license mix, more direct U.S. sales at lower discount, price increases, and production cost programs — achieved *despite* a strong Israeli shekel, higher component prices, and a low-margin hardware delivery to a Southeast Asian defense ministry. Management explicitly flagged more room: “there is definitely room for further gross margin improvements... We have already launched cost efficiency programs and cost savings programs within operations. And we have not yet seen the full effects of those.” — Tom Englund, CEO · 2026-11-12

Intuitive has quietly stopped being the story

The most interesting thing in this transcript is what is *not* there. A year ago the calls were dominated by the cancelled memorandum of understanding with Intuitive and a SEK 60–90 million revenue hole; the company's own keyword history shows attach rate as its single top theme in early 2026 and a top decliner by mid-year. This quarter, "attach rate" and "revenue loss" have both dropped out of the company's thematic top-30 entirely. In their place: potential for future license revenue and a broadening robotics customer base. Ask the analyst question anyway, and the answer is a flat refusal to quantify: “We see a lower impact than the SEK 60 million to SEK 90 million that we indicated earlier this year, and we stand by that statement also now for quarter 4. We have no new information to change that statement in any way.” — Tom Englund, CEO · 2026-11-12 Christian Lee's follow-up — why not narrow the range with under two months left in the year — went unanswered in substance, echoing the February call where management declined to break the same estimate down by quarter. The difference is the framing: in February that number was the whole investment case; in November it is a footnote to a license line that grew 16% to SEK 76 million on revenue from multiple robotics customers.

The customer base is broadening, and we are less dependent on any single customer than we were a year ago.

Tom Englund, CEO · 2026-11-12
Whether that claim holds is the open question. Intuitive's own da Vinci procedures are up 14% with a 12,000+ installed base; Medtronic expects Hugo at 250 installed systems by April; Stryker has just put money into CMR Surgical and Distalmotion. More robots, more trained surgeons, more simulation — the structural argument is intact even if the quarterly license line stays lumpy.

Aeris and the new ultrasound leg

The genuine novelty this quarter is product. Aeris, the point-of-care ultrasound simulator launched at EUSEM in Paris to 2,700 physicians, generated the majority of customer leads at the congress, took a CES Best of Innovation award, and has begun shipping in Q4. It is the first product built on the combined Surgical Science / Intelligent Ultrasound tech stack — the acquisition that was once a margin drag is now the source of the growth story. point-of-care ultrasound and Emergency medicine appear as fresh company themes for the first time; ultrasound simulation grew 14% and management now talks about a trainee population in the hundreds of thousands to millions. The read-across is deliberately unambitious on timing and ambitions everywhere else: “we don't expect Aeris to have a huge positive impact on our sales in this quarter, quarter 4, but rather an increasing positive impact throughout the year of next year.” — Tom Englund, CEO · 2026-11-12 A lower price point means a shorter sales cycle in theory — but budgets still need approval, so weeks become months.

The cash question finally has a date

With SEK 675 million of cash, no debt, and positive operating cash flow of SEK 43 million in the quarter, the perennial Q&A topic is capital allocation. Last call, the answer was a dead end: “We do not currently have that possibility. But there are different tools that we can then deploy.” — Tom Englund, CEO · 2026-08-19 This time there is a date — December 5, when First North rules allow buybacks under a mandate, with the Nasdaq Main Market uplift targeted for next year. Ahlberg's caveat is that no board decision exists yet, so this is optionality, not a promise. That is the shape of the whole quarter. Nothing is broken; nothing is accelerating either. Industry simulator sales to medical device companies were SEK 23 million against a strong prior year, and management conceded it was not happy with the development — but over 70% of active development projects are repeat customers, and service revenues grew 15% with the strongest September on record. Flat sales, target margins, a widening customer base and a new product entering a bigger market. The re-rating case now depends entirely on whether 2027 delivers the growth half of the equation.